Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer

Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion 131 to meet its primary endpoints, and future directions for atezolizumab research. The late-breaking abstract ‘IMpassion130: final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer’ (LBA16) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020.

Questions

1. Could you give us a brief overview of the IMpassion 130 study and its efficacy and safety findings? (0:29)
2. What have we learned from the final overall survival analysis of this study? (5:02)
3. What are your thoughts on the failure of IMpassion 131 to meet its primary endpoints? (6:00)
4. What are the implications of the findings of IMpassion 130 and 131 for future clinical practice? (8:33)
5. How can the efficacy of atezolizumab be improved in this hard-to-treat patient population, and what future studies are planned? (10:05)

Speaker Disclosures: Prof Leisha A Emens would like to declare the following: consulting/advisory board/honoraria – honoraria to self; AbbVie – honoraria; Amgen – honoraria; AstraZeneca – honoraria, travel/accommodation/expenses; Bayer – honoraria, travel/accommodation/expenses; Bristol Meyers Squibb – travel/accommodation/expenses; Celgene – honoraria; Chugai – honoraria; CytomX – no compensation; eTHeRNA – no compensation; Genentech – travel/accommodation/expenses; Gritstone – honoraria; Medimmune – honoraria; Molecuvax (potential for stock in future); Macrogenics – honoraria, travel/accommodation/expenses; Novartis – travel/accommodation/expenses; Peregrine – honoraria; Replimune – honoraria, travel/accommodation/expenses; Roche – travel/accommodation/expenses; Shionogi – advisory board, honoraria; Silverback – no compensation; Syndax – honoraria; Vaccinex – honoraria, travel/accommodation/expenses.

Support: Interview and filming supported by Touch Medical Media Ltd. The IMpassion trial was sponsored by F. Hoffmann-La Roche, Ltd.

Filmed in coverage of the Virtual 2020 ESMO Congress.